Clinical trials · Pennsylvania
Acute Lymphoblastic Leukemia clinical trials in Pennsylvania
We’re tracking 36 recruiting acute lymphoblastic leukemia studies with a site in Pennsylvania — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Pennsylvania
- NCT03959085RecruitingPhase 3
Inotuzumab plus chemotherapy for high-risk childhood leukemia
This Phase 3 trial tests whether adding inotuzumab to standard post-induction chemotherapy improves outcomes for children and young teens with high-risk B-ALL, mixed phenotype acute leukemia (MPAL), or certain high-risk B-LLy. It may help by targeting leukemia cells more directly, but participation depends on specific age, lab results, and medical history rules.
Hershey, PennsylvaniaAges 12 months–25 years - NCT03970096RecruitingPhase 2
Reduce graft-versus-host disease after stem cell transplant
This Phase 2 study tests ways to lower the risk of graft-versus-host disease (GVHD), a serious complication after an allogeneic stem cell transplant from a matched donor. It is for people with acute leukemia or MDS who are going to receive intensive conditioning therapy, aiming to improve safety while keeping the transplant effective.
Pittsburgh, PennsylvaniaAges 1–60 - NCT03739814RecruitingPhase 2
Test inotuzumab, blinatumomab, and possibly ponatinib for CD22 ALL
This Phase 2 study tests a combination of medicines (inotuzumab ozogamicin and blinatumomab), with or without ponatinib, for people with CD22-positive B-cell acute lymphoblastic leukemia (ALL). It aims to improve remission and control leukemia cells, including in the bone marrow.
Allentown, PennsylvaniaAges 18 years+ - NCT03810196Recruiting
Stem cell addback after transplant to treat viral or fungal infection
This study tests a stem cell “addback” treatment after a specific type of transplant (with certain immune cells removed). It may help the body recover faster and fight serious viral or fungal infections in children and teens.
Philadelphia, PennsylvaniaAges Up to 25 years - NCT03150693RecruitingPhase 3
New treatment for young adults with CD22-positive ALL
This Phase 3 trial tests adding inotuzumab ozogamicin to standard chemotherapy for newly diagnosed CD22-positive B-cell acute lymphoblastic leukemia (ALL). It may help more patients achieve remission and reduce the risk of the leukemia coming back, while also checking safety and tolerability.
Allentown, PennsylvaniaAges 18–39 - NCT02646839Enrolling by invitationPhase 2
Testing a gene-matched transplant approach for childhood leukemia
This trial studies a specific type of partially matched (haploidentical) stem cell transplant in children with ALL, AML, or MDS. It looks at whether using certain immune system gene patterns (KIR) and measuring leftover disease after treatment can improve outcomes and cost-effectiveness.
Philadelphia, PennsylvaniaAges Up to 21 years - NCT01351545Recruiting
Cryopreserved cord blood access program for transplant patients
This trial studies an organized way to obtain and distribute unlicensed (not FDA-approved for general use) stored cord blood units that have been frozen and kept. It may help people who need a cord blood transplant but don’t fit the “licensed cord blood only” options.
Hershey, PennsylvaniaAges Any age - NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
Philadelphia, PennsylvaniaAges 1–21 - NCT05480449RecruitingPhase 1/Phase 2
Personalized CAR-T for children with high-risk B-ALL
This trial studies a personalized type of immune therapy (CAR-T) made from your own cells to treat pediatric B-ALL that has returned or not responded to prior treatment. It aims to see how well this manufactured CAR-T works and how safely it can be given.
Philadelphia, PennsylvaniaAges birth–29 years - NCT06395103RecruitingPhase 1/Phase 2
Zilovertamab vedotin for blood cancers and solid tumors
This trial tests a new drug called zilovertamab vedotin for children and young adults with certain blood cancers or solid tumors. The drug is designed to target and kill cancer cells, and the study will see if it is safe and effective.
Philadelphia, PennsylvaniaAges 6 months–25 years - NCT05082519RecruitingPhase 2
Calorie restriction and exercise to improve leukemia treatment in young patients
This study tests whether a special diet (calorie restriction) and increased physical activity can make chemotherapy work better for young people with B-ALL. Participants will follow a monitored diet and exercise plan during their first month of treatment.
Philadelphia, PennsylvaniaAges 7–25 - NCT05194397RecruitingPhase 2
Exercise plus NR supplement to boost fitness after stem-cell transplant
This trial tests whether a supervised exercise program, plus an NR supplement, can improve fitness in young people who have had an allogeneic (donor) stem-cell transplant for certain blood cancers or bone marrow conditions. It’s meant to help with energy and physical ability while monitoring safety.
Philadelphia, PennsylvaniaAges 10–30
Acute Lymphoblastic Leukemia trials by city in Pennsylvania
Where these studies are running in Pennsylvania
Institutions with a site for the recruiting acute lymphoblastic leukemia studies listed above.
- Children's Hospital of Philadelphia · 9 studies
- Lehigh Valley Hospital-Cedar Crest · 3 studies
- Lehigh Valley Hospital - Muhlenberg · 2 studies
- Lehigh Valley Hospital-Hazleton · 2 studies
- Pocono Medical Center · 2 studies
- Thomas Jefferson University Hospital · 2 studies
- Children's Hospital of Pittsburgh
- Christiana Care Health System-Concord Health Center
What taking part in a acute lymphoblastic leukemia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Acute Lymphoblastic Leukemia trials in other states
Common questions
- Are there acute lymphoblastic leukemia clinical trials in Pennsylvania?
- Yes. We're currently tracking 36 recruiting acute lymphoblastic leukemia studies with a site in Pennsylvania, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a acute lymphoblastic leukemia study in Pennsylvania?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Pennsylvania to take part?
- Not necessarily. These studies have a site in Pennsylvania, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a acute lymphoblastic leukemia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New acute lymphoblastic leukemia studies open in Pennsylvania regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.